Cardio

Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists’ Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week

Retrieved on: 
星期一, 五月 13, 2024
Cardiology, Telemedicine, Virtual Medicine, Health, Medical Devices, Family, Genetics, Health Insurance, Consumer, FMS, Patient, Cardio, Organization, CHD, Bain & Company, Conditional sentence, Ebbs, MBA, Family medicine, Entrepreneurship

This launch in a retail healthcare setting is an expansion to existing and new patients in the area.

Key Points: 
  • This launch in a retail healthcare setting is an expansion to existing and new patients in the area.
  • During FMS's operating hours, seven days a week, patients can undergo a simple blood draw to receive Cardio Diagnostics' epigenetic-genetic tests, if determined by the provider to be medically necessary.
  • Cardio Diagnostics’ epigenetic-genetic tests provide personalized insights into heart attack risk and coronary heart disease status.
  • This strategic alliance democratizes access to top-tier heart disease services and propels Cardio Diagnostics as a cardiovascular retail healthcare innovation leader.

Midol® Addresses Period Education and Normalization of Menstrual Discomfort with PeriodTalk Initiative in Partnership with Nonprofit PERIOD.

Retrieved on: 
星期四, 五月 9, 2024
Women, Fitness & Nutrition, Philanthropy, Other Education, Health, Consumer, General Health, Other Philanthropy, Education, Menstrual cycle, Cardio, Breast, Bleeding, OB/GYN, Food, Bloating, Disease, Patient, Work, Bayer, Comfort, Multimedia, Knowledge, Birth control

launched the PeriodTalk with Midol campaign to help bring further awareness to the gaps in period education and dialogue to ultimately mend the discrepancies.

Key Points: 
  • launched the PeriodTalk with Midol campaign to help bring further awareness to the gaps in period education and dialogue to ultimately mend the discrepancies.
  • View the full release here: https://www.businesswire.com/news/home/20240509301202/en/
    As part of the PeriodTalk campaign, Midol and PERIOD.
  • Midol’s latest survey revealed over 85% of respondents reported their period symptoms have impacted their daily lives within the past 3 months.
  • as hosts of PeriodTalk: a candid roundtable conversation focused on normalizing “uncomfortable” period discussions and enabling others to help end the normalization of discomfort.

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Retrieved on: 
星期二, 四月 9, 2024
Cardiology, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Medical Devices, Artificial Intelligence, Genetics, Diagnosis, Exponential, Cardio, Genomics, Cardiovascular disease, Growth, Entrepreneurship, Partnership, Risk, Patient, Artificial intelligence, Splenic infarction, Death, CHD, Medicine, Concierge medicine, Epigenomics, Moyamoya disease, USD, Medical device

As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Key Points: 
  • As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.
  • Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions.
  • "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Integrating Cardio Diagnostics' advanced tests into Exponential Health's offerings is a proactive step toward mitigating this global health challenge.

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session

Retrieved on: 
星期四, 三月 14, 2024
Other Health, Software, General Health, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, Other Technology, Health, Cardio, Genomics, Organization, Cardiovascular disease, ACI, Entrepreneurship, Patient, Artificial intelligence, Medicine, CHD, American College, Heart, Epigenomics, Moyamoya disease, ACC, Pharmaceutical industry

Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."

Key Points: 
  • Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."
  • All attendees including providers, provider organizations and potential industry partners will be able to learn more about Cardio Diagnostics' HeartRisk and Actionable Clinical Intelligence platforms at booth 3605.
  • Actionable Clinical Intelligence V.3: Building upon the success of its predecessor, which debuted at ACC in 2023, Actionable Clinical Intelligence V.3 takes precision medicine to new heights.
  • "Our new innovative solutions, HeartRisk and Actionable Clinical Intelligence V.3, can potentially revolutionize how healthcare professionals approach cardiovascular disease prevention, detection and management.

Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

Retrieved on: 
星期四, 二月 15, 2024
General Health, Professional Services, Data Management, Technology, State, Local, Artificial Intelligence, Data Analytics, Cardiology, Biotechnology, Human Resources, Health, Public Policy, Government, Prison, Intelligence, Investment, Smoking, Transport, Conditional sentence, CVD, Cardiovascular disease, Entrepreneurship, Risk, Consultant, Prevalence, Cardio, CHD, Hypertension, Death, Organization, Medicine, Workforce, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.
  • This expansion extends the reach of its proprietary data intelligence platform to correctional facilities, risk-bearing providers engaged in value-based contracts, and broker and benefits consultants.
  • "By expanding our HeartRisk™ platform, we're not just innovating within traditional healthcare sectors but breaking new ground in diverse markets.
  • From correctional facilities to value-based care providers and workplace wellness programs to brokerage and benefits consultants, our precision cardiovascular solutions provide actionable insights.

Integer to Showcase Recently Acquired Capabilities and New Technologies at MD&M West 2024

Retrieved on: 
星期四, 二月 1, 2024
Neuromodulation, Electrophysiology, MD, Integer, Patient, Gen, Second generation, Anaheim Convention Center, Risk, Acquisition, Cardio, Arrhythmia, Blood vessel, Medical imaging

PLANO, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leader in medical device outsource manufacturing, will join innovators and industry leaders around the world in exhibiting at MD&M West, Feb. 6-8, 2024, at the Anaheim Convention Center in Anaheim, California.

Key Points: 
  • Integer’s exhibit will spotlight the recent strategic acquisitions of InNeuroCo and Pulse Technologies, each of which have further enhanced Integer’s capability spectrum in the medical device sector.
  • The acquisition of InNeuroCo brings specific expertise in neurovascular solutions and advanced catheter technologies, while the combination with Pulse Technologies enhances capabilities in precision micro machining, backed by proprietary technologies and a focus on high-growth medical markets.
  • Cardio and Vascular Solutions: A full range of electrophysiology, structural heart, and neurovascular product solutions including high-performing guidewires, steerable introducers and sheaths, therapy delivery systems, and implant technologies.
  • In addition to Integer’s exhibit at booth #1439, MD&M West 2024 attendees can also visit Pulse Technologies at booth #2844 to learn more about complex micro machining for critical medical device components.

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Retrieved on: 
星期三, 一月 24, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Genetics, Nuclear medicine, Entrepreneurship, Artificial intelligence, Patient, Internal medicine, Research, American College of Physicians, MD, Cardio, Emory University, JACC, Innovation, University, Algorithm, Journal of Clinical Investigation, FACC, ACP, ACC, Journal, NIH, Cardiovascular disease, Bachelor of Science, Hospital, Society for Vascular Surgery, Mount Sinai School, American College, Growth, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.
  • The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion.
  • “I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee.
  • Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care.

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India

Retrieved on: 
星期一, 一月 8, 2024
Science, Cardiology, Biotechnology, Research, General Health, Health, Artificial Intelligence, Technology, Genotype, Integration, MD, CHD, Risk, Patent, University, Cardio, Patient, University of Iowa, Cardiovascular disease, Public health, Distribution, Algorithm, Personalized medicine, Pharmaceutical industry

It was co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively.

Key Points: 
  • It was co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively.
  • This presents a significant opportunity for Cardio Diagnostics to expand its footprint in the world’s fastest growing nation by population .
  • Cardio Diagnostics recently entered into a Supply and Distribution Agreement with Aimil Ltd. , a company at the forefront of the instrumentation industry in India since 1932 with 14 sales and services offices across India.
  • Cardio Diagnostics exemplifies the transformation of cutting-edge research into Precision Medicine solutions with the potential to impact and save lives worldwide."

Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors

Retrieved on: 
星期四, 十二月 21, 2023
Health, Technology, General Health, Artificial Intelligence, Cardiology, Biotechnology, Entrepreneurship, Audit committee, FDA, MBA, Doctor of Philosophy, Health equity, University, Citigroup, Cardio, Therapy

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.
  • Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity.
  • "We are thrilled to welcome Paul to Cardio Diagnostics’ Board of Directors," said CEO and Co-Founder Meesha Dogan, PhD.
  • "I am thrilled to join the Cardio Diagnostics board to help drive the next wave of cardiovascular innovation," said Paul Burton, J.D., MBA, Managing Partner at 2Flo Ventures.

BowFlex Inc. Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
星期二, 十一月 14, 2023
Retail, Health, Technology, Fitness & Nutrition, Mobile, Wireless, Specialty, Hardware, Trade, EBITDA, Webcast, Absorption, Feedback, Acquisition, NYSE, Balance sheet, Strength, Motion, Income tax, Advertising, All Access Europe, Investment, Comparison, Cardio, Tax, Public expenditure, PPT, Member, Marketing, Machine learning, Capital, Bowflex, Capital expenditure, Adjustment, Forecasting, Operating cost, BFX, VAY, Growth, Subscription business model, IOS, Lender option borrower option, Environment, Rare-earth element, Music, Aquaculture, Reinsurance, Bookkeeping, Cryptocurrency, Pharmaceutical industry, Mobile phone, Video game, Health care, Android

BowFlex Inc. (NYSE: BFX) today reported its unaudited operating results for the fiscal 2024 second quarter ended September 30, 2023.

Key Points: 
  • BowFlex Inc. (NYSE: BFX) today reported its unaudited operating results for the fiscal 2024 second quarter ended September 30, 2023.
  • Fiscal 2024 Second Quarter Ended September 30, 2023 Compared to September 30, 2022
    Direct segment sales were $20.7 million, compared to $24.5 million, a decline of 15.3% versus the same period in 2022.
  • The increase in inventory in the second quarter of fiscal 2024 versus the fiscal year ended March 31, 2023 was driven by inventory purchases in anticipation of our busy season, which occurs in the third and fourth quarters of our fiscal year.
  • The increase in trade receivables was due to increased Retail sales offset by cash collection efforts in the second quarter of fiscal 2024.